<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2180">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132777</url>
  </required_header>
  <id_info>
    <org_study_id>JMT101-CSP-003</org_study_id>
    <nct_id>NCT05132777</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai JMT-Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai JMT-Bio Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase II, open label, multi-center study to evaluate the efficacy and safety&#xD;
      of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small&#xD;
      cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1</measure>
    <time_frame>From the first dose to disease progression or end of study, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed ORR Assessed by the Investigator per RECIST Version 1.1</measure>
    <time_frame>From the first dose to disease progression or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From the first dose to disease progression or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From the first dose to disease progression or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the first dose to disease progression or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the first dose to death or end of study, an average of 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAEV5.0))</measure>
    <time_frame>From the enrollment until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of JMT101</measure>
    <time_frame>From the enrollment until 30 days after the last dose</time_frame>
    <description>Blood samples will be collected at specified timepoints to detect the presence of anti-drug antibodies and neutralizing antibodies against JMT101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve from time 0 to the concentration at last time point (AUC0-last) of JMT101.</measure>
    <time_frame>From the first dose to cycle 3 day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration (Cmax) of JMT101.</measure>
    <time_frame>From the first dose to cycle 3 day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of JMT101.</measure>
    <time_frame>From the first dose to cycle 3 day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of JMT101.</measure>
    <time_frame>From the first dose to cycle 3 day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl/F of JMT101.</measure>
    <time_frame>From the first dose to cycle 3 day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of cancer-related biomarkers in circulating tumor DNA from plasma to analyse the corcorrelation with clinical efficacy and drug resistance.</measure>
    <time_frame>From the enrollment to disease progression, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Locally Advanced or Metastatic Non-Small Cell Lung Cancer</condition>
  <condition>EGFR Exon20 Insertion Mutations</condition>
  <arm_group>
    <arm_group_label>JMT101 in combination with Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JMT101</intervention_name>
    <description>JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).</description>
    <arm_group_label>JMT101 in combination with Osimertinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib Mesylate Tablets</intervention_name>
    <description>Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).</description>
    <arm_group_label>JMT101 in combination with Osimertinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥18 years.&#xD;
&#xD;
          2. Patients with non-irradiable, non-operable, histologically or cytologically confirmed&#xD;
             Stage IIIB~IV NSCLC, harboring an EGFR exon 20 insertion mutation (including&#xD;
             duplication mutations), who have progressed on or intolerable to prior platinum-based&#xD;
             chemotherapy.&#xD;
&#xD;
          3. At least 1 measurable lesion according to RECIST 1.1.&#xD;
&#xD;
          4. ECOG score 0 or 1.&#xD;
&#xD;
          5. Life expectancy≥3 months.&#xD;
&#xD;
          6. Adequate organ function(tested within 7 days prior to the first dose): Absolute&#xD;
             neutrophil count (ANC)≥1.5×10^9 /L, Platelets≥90×10^9/L, Hemoglobin≥9 g/dL or ≥5.6&#xD;
             mmol/L; Serum creatinine &lt;1.5 × ULN; Total bilirubin ≤1.5×ULN (if liver metastases are&#xD;
             present,≤3×ULN), AST and ALT≤3×ULN (if liver metastases are present,≤5×ULN)；INR or&#xD;
             PT≤1.5×ULN, APTT≤1.5×ULN.&#xD;
&#xD;
          7. A female of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to the first dose. Any male and female patient of childbearing potential&#xD;
             must agree to use effective contraception method throughout the trial period and for&#xD;
             another half year after the end of the trial.&#xD;
&#xD;
          8. Fully understand and fully informed of this study; must sign and give the written&#xD;
             Informed Consent Form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously received monoclonal antibody therapy targeting EGFR.&#xD;
&#xD;
          2. Previous chemotherapy, biotherapy, targeted therapy, immunotherapy or other anti-tumor&#xD;
             treatment within 4 weeks prior to the first dose of the study drug, 2 weeks (or 5&#xD;
             half-lives whichever is longer) for using small molecule targeted drugs, 2 weeks for&#xD;
             using radiotherapy..&#xD;
&#xD;
          3. Treated with other investigational agents within 4 weeks prior to the first dose of&#xD;
             the study drug.&#xD;
&#xD;
          4. Experienced any major surgery (excluding puncture biopsy) or significant trauma within&#xD;
             4 weeks prior to the first dose.&#xD;
&#xD;
          5. Hypersensitivity or intolerance to our study drug or any excipients of the study drug.&#xD;
&#xD;
          6. Received strong or moderate inducers of CYP3A4 within 14 days prior to the first dose.&#xD;
&#xD;
          7. The adverse reactions of previous antitumor treatment have not yet recovered to Grade≤&#xD;
             1 based on CTCAE 5.0 or baseline (except for the toxicity without safety risk judged&#xD;
             by the investigator, such as alopecia).&#xD;
&#xD;
          8. Had untreated central nervous system metastasis or meningeal metastasis.&#xD;
&#xD;
          9. History of autoimmune disease, immunodeficiency, including HIV positive, or the&#xD;
             presence of other acquired or congenital immunodeficiency, or organ transplantation.&#xD;
&#xD;
         10. Active hepatitis B, hepatitis C virus or syphilis infection.&#xD;
&#xD;
         11. History of severe cardiovascular disease.&#xD;
&#xD;
         12. Have difficulty with swallowing medications, or there is a condition seriously&#xD;
             affecting the gastrointestinal absorption as judged by investigators.&#xD;
&#xD;
         13. Other malignant tumors diagnosed within 5 years prior to the first dose, with the&#xD;
             exception of adequately treated skin basal cell carcinoma, skin squamous cell&#xD;
             carcinoma, preinvasive cervical carcinoma or breast cancer that was effectively&#xD;
             removed and not requiring or not expected to require other treatment during the study&#xD;
             period.&#xD;
&#xD;
         14. History of interstitial lung disease, drug-induced interstitial lung disease,&#xD;
             radioactive pneumonia requiring steroid treatment, or any evidence of clinical active&#xD;
             interstitial lung disease.&#xD;
&#xD;
         15. History of other serious systemic diseases, in the judgment of the investigator, that&#xD;
             make the subject unfit for the study.&#xD;
&#xD;
         16. Alcohol or drug dependence.&#xD;
&#xD;
         17. Had an unequivocal history of neurological or psychiatric disorders, including&#xD;
             epilepsy or dementia.&#xD;
&#xD;
         18. Pregnant or lactating woman.&#xD;
&#xD;
         19. Not suitable for this study as determined by the investigator due to other reasons.&#xD;
&#xD;
         20. Patients harboring EGFR exon20 insertion mutation and also have other EGFR&#xD;
             TKI-sensitizing EGFR mutations, such as G719X mutation in exon 18, exon 19 deletion&#xD;
             mutation (19 del), exon 20 T790M or S768I mutation, exon 21 L858R mutation, or L861Q&#xD;
             mutation.&#xD;
&#xD;
         21. Previously received drugs that developed for EGFR exon20 insertion mutated NSCLC (&#xD;
             such as TAK-788, Poziotinib, DZD9008 or JNJ-61186372); the short-term use is allowed,&#xD;
             such as≤2 weeks. Responsive to previous EGFR-TKI treatment (including the best overall&#xD;
             response of complete response, partial response, or stable disease last more than 6&#xD;
             months). Previously received PD-1 or PD-L1 monoclonal antibody therapy within 3 months&#xD;
             prior to the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiugao Yang</last_name>
    <phone>+86-21-60677906</phone>
    <email>yangxiugao@mail.ecspc.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

